These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 30626851)

  • 1. [Regorafenib in patients with advanced hepatocellular carcinoma;current status and future perspective].
    Ogasawara S; Ooka Y; Kato N
    Nihon Shokakibyo Gakkai Zasshi; 2019; 116(1):28-35. PubMed ID: 30626851
    [No Abstract]   [Full Text] [Related]  

  • 2. Regorafenib for treatment of hepatocellular carcinoma.
    Sherman M
    Hepatology; 2018 Mar; 67(3):1162-1165. PubMed ID: 29059458
    [No Abstract]   [Full Text] [Related]  

  • 3. Regorafenib: a newly approved drug for advanced hepatocellular carcinoma.
    Kyrochristos ID; Ziogas DE; Roukos DH
    Future Oncol; 2017 Aug; 13(19):1665-1668. PubMed ID: 28613123
    [No Abstract]   [Full Text] [Related]  

  • 4. Regorafenib as treatment for patients with advanced hepatocellular cancer.
    Thillai K; Srikandarajah K; Ross P
    Future Oncol; 2017 Oct; 13(25):2223-2232. PubMed ID: 28766967
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Health policy: Me-too drugs with limited benefits - the tale of regorafenib for HCC.
    Gyawali B; Prasad V
    Nat Rev Clin Oncol; 2017 Nov; 14(11):653-654. PubMed ID: 28719584
    [No Abstract]   [Full Text] [Related]  

  • 6. Successful Treatment of Hepatocellular Carcinoma with Regorafenib after Sorafenib-induced Hypersensitivity.
    Yoshioka N; Kuzuya T; Ito T; Ishizu Y; Honda T; Ishikawa T; Ishigami M; Fujishiro M
    Intern Med; 2019 Oct; 58(19):2803-2808. PubMed ID: 31243207
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of regorafenib in hepatocellular carcinoma.
    Frenette CT
    Clin Adv Hematol Oncol; 2017 Feb; 15(2):121-123. PubMed ID: 28398282
    [No Abstract]   [Full Text] [Related]  

  • 8. Immune oncology in hepatocellular carcinoma-hype and hope.
    Wörns MA; Galle PR
    Lancet; 2017 Jun; 389(10088):2448-2449. PubMed ID: 28434649
    [No Abstract]   [Full Text] [Related]  

  • 9. Regorafenib for the treatment of hepatocellular carcinoma.
    Tovoli F; Granito A; De Lorenzo S; Bolondi L
    Drugs Today (Barc); 2018 Jan; 54(1):5-13. PubMed ID: 29569657
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regorafenib Approved for Liver Cancer.
    Cancer Discov; 2017 Jul; 7(7):660. PubMed ID: 28522682
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Current status and future perspective of sorafenib for advanced hepatocellular carcinoma].
    Ikeda M; Mitsunaga S; Shimizu S; Ohno I; Takahashi H; Okuyama H; Kuwahara A; Okusaka T
    Nihon Shokakibyo Gakkai Zasshi; 2012 Aug; 109(8):1346-54. PubMed ID: 22863957
    [No Abstract]   [Full Text] [Related]  

  • 12. Regorafenib: A Review in Hepatocellular Carcinoma.
    Heo YA; Syed YY
    Drugs; 2018 Jun; 78(9):951-958. PubMed ID: 29915898
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exposure-response relationship of regorafenib efficacy in patients with hepatocellular carcinoma.
    Solms A; Reinecke I; Fiala-Buskies S; Keunecke A; Drenth HJ; Bruix J; Meinhardt G; Cleton A; Ploeger B
    Eur J Pharm Sci; 2017 Nov; 109S():S149-S153. PubMed ID: 28549676
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost effectiveness of regorafenib as second-line therapy for patients with advanced hepatocellular carcinoma.
    Parikh ND; Singal AG; Hutton DW
    Cancer; 2017 Oct; 123(19):3725-3731. PubMed ID: 28662266
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regorafenib for the treatment of unresectable hepatocellular carcinoma.
    Rimassa L; Pressiani T; Personeni N; Santoro A
    Expert Rev Anticancer Ther; 2017 Jul; 17(7):567-576. PubMed ID: 28580808
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Angiopoietin-2/Tie2 Inhibition by Regorafenib Associates With Striking Response in a Patient With Aggressive Hepatocellular Carcinoma.
    Todesca P; Marzi L; Critelli RM; Cuffari B; Caporali C; Turco L; Pinelli G; Schepis F; Carulli L; de Maria N; Casari F; Scaglioni R; Villa E
    Hepatology; 2019 Aug; 70(2):745-747. PubMed ID: 30802985
    [No Abstract]   [Full Text] [Related]  

  • 17. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Bruix J; Qin S; Merle P; Granito A; Huang YH; Bodoky G; Pracht M; Yokosuka O; Rosmorduc O; Breder V; Gerolami R; Masi G; Ross PJ; Song T; Bronowicki JP; Ollivier-Hourmand I; Kudo M; Cheng AL; Llovet JM; Finn RS; LeBerre MA; Baumhauer A; Meinhardt G; Han G;
    Lancet; 2017 Jan; 389(10064):56-66. PubMed ID: 27932229
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of cellular, molecular and tumor microenvironment in hepatocellular carcinoma: Possible targets and future directions in the regorafenib era.
    Juengpanich S; Topatana W; Lu C; Staiculescu D; Li S; Cao J; Lin J; Hu J; Chen M; Chen J; Cai X
    Int J Cancer; 2020 Oct; 147(7):1778-1792. PubMed ID: 32162677
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New Approvals in Cancer Treatment.
    Aschenbrenner DS
    Am J Nurs; 2017 Aug; 117(8):22. PubMed ID: 28749878
    [No Abstract]   [Full Text] [Related]  

  • 20. Regorafenib as second-line therapy for intermediate or advanced hepatocellular carcinoma: multicentre, open-label, phase II safety study.
    Bruix J; Tak WY; Gasbarrini A; Santoro A; Colombo M; Lim HY; Mazzaferro V; Wiest R; Reig M; Wagner A; Bolondi L
    Eur J Cancer; 2013 Nov; 49(16):3412-9. PubMed ID: 23809766
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.